Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

ALAMEDA, Calif., May 28, 2026 — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the Jefferies Global Healthcare Conference taking place June 2-4, 2026 in New York, New York.

Details of Dr. Mendelsohn’s presentation are as follows:

Date: Thursday, June 4, 2026 Time: 11:05 a.m. - 11:35 a.m. Eastern Time Location: New York Marriott Marquis, 1535 Broadway

Following the presentation, a replay will be available for 90 days on the Investors section of the Vivani corporate website at https://vivani.com.

More information about the Jefferies Global Healthcare Conference can be found at https://www.jefferies.com/events/global-healthcare-conference-in-new-york/.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: https://vivani.com.